ImmunityBio Inc. (NASDAQ: IBRX) announced the launch of ResQ215B, a phase 2 clinical study testing a chemotherapy-free treatment combination for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE